Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/81682
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Rehabilitation Sciences | en_US |
dc.creator | Vanicek, T | en_US |
dc.creator | Kranz, GS | en_US |
dc.creator | Vyssoki, B | en_US |
dc.creator | Komorowski, A | en_US |
dc.creator | Fugger, G | en_US |
dc.creator | Hoflich, A | en_US |
dc.creator | Micskei, Z | en_US |
dc.creator | Milovic, S | en_US |
dc.creator | Lanzenberger, R | en_US |
dc.creator | Eckert, A | en_US |
dc.creator | Kasper, S | en_US |
dc.creator | Frey, R | en_US |
dc.date.accessioned | 2020-02-10T12:28:37Z | - |
dc.date.available | 2020-02-10T12:28:37Z | - |
dc.identifier.issn | 0001-690X | en_US |
dc.identifier.uri | http://hdl.handle.net/10397/81682 | - |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.rights | ©2019 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd | en_US |
dc.rights | All rights reserved | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_US |
dc.rights | The following publication Vanicek, T., Kranz, G. S., Vyssoki, B., Komorowski, A., Fugger, G., Hoflich, A., . . . Frey, R. (2019). Repetitive enhancement of serum BDNF subsequent to continuation ECT. Acta Psychiatrica Scandinavica, 140(5), 426-434 is available at https://dx.doi.org/10.1111/acps.13080 | en_US |
dc.subject | Depression | en_US |
dc.subject | Unipolar and bipolar affective disorder | en_US |
dc.subject | Continuation electroconvulsive therapy | en_US |
dc.subject | Brain-derived neurotrophic factor | en_US |
dc.title | Repetitive enhancement of serum BDNF subsequent to continuation ECT | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 426 | en_US |
dc.identifier.epage | 434 | en_US |
dc.identifier.volume | 140 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.doi | 10.1111/acps.13080 | en_US |
dcterms.abstract | Introduction: Continuation electroconvulsive therapy (c-ECT) is highly effective for the prevention of depressive symptom relapse. There is a lack of understanding, about how c-ECT works in humans, particularly with regard to its effects on brain derived neurotrophic factor (BDNF) concentrations. Here, we aimed to close a gap in the literature by evaluating BDNF levels in patients receiving c-ECT. | en_US |
dcterms.abstract | Methods: We included 13 patients with either unipolar or bipolar depression (mean age +/- SD: 55.5 +/- 17.1; f/m: 10/3; unipolar/bipolar: 10/3) who received between one and four c-ECT (average per patient: 2.8). Serum BDNF (sBDNF) levels were assessed before and after each c-ECT sessions. Clinical assessments were also administered both before and after treatment. | en_US |
dcterms.abstract | Results: Our analysis revealed a significant increase in sBDNF after each treatment (c-ECT 1-3: P < 0.001, c-ECT 4: P = 0.018). The application of multiple c-ECT treatments was not, however, associated with further sBDNF enhancements. Psychometric scores were not significantly altered following c-ECT. | en_US |
dcterms.abstract | Discussion: An increase in sBDNF concentrations subsequent to c-ECT parallel data from the animal literature, which has linked regularly applied electrical stimulation to neuroplastic processes. This finding suggests a relationship between ECT-induced sBDNF concentrations and (sustained) remission status, considering a stable clinical condition across c-ECT. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Acta psychiatrica Scandinavica, Nov. 2019, v. 140, no. 5, p. 426-434 | en_US |
dcterms.isPartOf | Acta psychiatrica Scandinavica | en_US |
dcterms.issued | 2019-11 | - |
dc.identifier.isi | WOS:000486279700001 | - |
dc.identifier.scopus | 2-s2.0-85073791232 | - |
dc.identifier.eissn | 1600-0447 | en_US |
dc.description.validate | 202002 bcrc | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | a0723-n08, OA_Scopus/WOS | en_US |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | Austrian National Bank (P23021) | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Vanicek_Serum_BDNF_Subsequent_ECT.pdf | 401.75 kB | Adobe PDF | View/Open |
Page views
62
Citations as of Jun 26, 2022
Downloads
57
Citations as of Jun 26, 2022
SCOPUSTM
Citations
9
Citations as of Jun 23, 2022
WEB OF SCIENCETM
Citations
9
Citations as of Jun 23, 2022

Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.